174 related articles for article (PubMed ID: 8704254)
1. Tumor vaccination with macrophage colony-stimulating factor-producing Lewis lung carcinoma in mice.
Morita T; Ikeda K; Douzono M; Yamada M; Kimura F; Kawakami K; Sasaki K; Motoyoshi K; Takahara J; Irino S
Blood; 1996 Aug; 88(3):955-61. PubMed ID: 8704254
[TBL] [Abstract][Full Text] [Related]
2. Antitumor immunity induced by irradiated tumor cells producing macrophage colony-stimulating factor.
Suzu S; Kimura F; Tanaka-Douzono M; Yamada M; Nakamura Y; Wakimoto N; Sato K; Morita T; Ikeda K; Motoyoshi K
Int J Hematol; 2001 Apr; 73(3):378-82. PubMed ID: 11345206
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of GM-CSF-producing tumor vaccine after docetaxel chemotherapy in mice bearing established Lewis lung carcinoma.
Chu Y; Wang LX; Yang G; Ross HJ; Urba WJ; Prell R; Jooss K; Xiong S; Hu HM
J Immunother; 2006; 29(4):367-80. PubMed ID: 16799332
[TBL] [Abstract][Full Text] [Related]
4. Fractalkine transgene induces T-cell-dependent antitumor immunity through chemoattraction and activation of dendritic cells.
Guo J; Zhang M; Wang B; Yuan Z; Guo Z; Chen T; Yu Y; Qin Z; Cao X
Int J Cancer; 2003 Jan; 103(2):212-20. PubMed ID: 12455035
[TBL] [Abstract][Full Text] [Related]
5. Big tumor regression induced by GM-CSF gene-modified 3LL tumor cells via facilitating DC maturation and deviation toward CD11c+CD8alpha+ subset.
Lin Y; Xiong S; Zhang L; Zhang Y; Cai Y; Xu L; Chu Y
DNA Cell Biol; 2007 Dec; 26(12):863-72. PubMed ID: 17760559
[TBL] [Abstract][Full Text] [Related]
6. Hsp110 over-expression increases the immunogenicity of the murine CT26 colon tumor.
Wang XY; Li Y; Manjili MH; Repasky EA; Pardoll DM; Subjeck JR
Cancer Immunol Immunother; 2002 Aug; 51(6):311-9. PubMed ID: 12111119
[TBL] [Abstract][Full Text] [Related]
7. Cellular immunotherapy using irradiated lung cancer cell vaccine co-expressing GM-CSF and IL-18 can induce significant antitumor effects.
Tian H; Shi G; Yang G; Zhang J; Li Y; Du T; Wang J; Xu F; Cheng L; Zhang X; Dai L; Chen X; Zhang S; Yang Y; Yu D; Wei Y; Deng H
BMC Cancer; 2014 Jan; 14():48. PubMed ID: 24475975
[TBL] [Abstract][Full Text] [Related]
8. GM-CSF and B7-1 (CD80) co-stimulatory signals co-operate in the induction of effective anti-tumor immunity in syngeneic mice.
Sumimoto H; Tani K; Nakazaki Y; Tanabe T; Hibino H; Hamada H; Azuma M; Asano S
Int J Cancer; 1997 Nov; 73(4):556-61. PubMed ID: 9389572
[TBL] [Abstract][Full Text] [Related]
9. Chemoattraction, adhesion and activation of natural killer cells are involved in the antitumor immune response induced by fractalkine/CX3CL1.
Guo J; Chen T; Wang B; Zhang M; An H; Guo Z; Yu Y; Qin Z; Cao X
Immunol Lett; 2003 Oct; 89(1):1-7. PubMed ID: 12946858
[TBL] [Abstract][Full Text] [Related]
10. Non-immunogenic murine hepatocellular carcinoma Hepa1-6 cells expressing the membrane form of macrophage colony stimulating factor are rejected in vivo and lead to CD8+ T-cell immunity against the parental tumor.
Dan Q; Sanchez R; Delgado C; Wepsic HT; Morgan K; Chen Y; Jeffes EW; Lowell CA; Morgan TR; Jadus MR
Mol Ther; 2001 Nov; 4(5):427-37. PubMed ID: 11708879
[TBL] [Abstract][Full Text] [Related]
11. Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system.
Sampson JH; Archer GE; Ashley DM; Fuchs HE; Hale LP; Dranoff G; Bigner DD
Proc Natl Acad Sci U S A; 1996 Sep; 93(19):10399-404. PubMed ID: 8816812
[TBL] [Abstract][Full Text] [Related]
12. TLR7 ligand augments GM-CSF-initiated antitumor immunity through activation of plasmacytoid dendritic cells.
Narusawa M; Inoue H; Sakamoto C; Matsumura Y; Takahashi A; Inoue T; Watanabe A; Miyamoto S; Miura Y; Hijikata Y; Tanaka Y; Inoue M; Takayama K; Okazaki T; Hasegawa M; Nakanishi Y; Tani K
Cancer Immunol Res; 2014 Jun; 2(6):568-80. PubMed ID: 24830413
[TBL] [Abstract][Full Text] [Related]
13. Superiority of interleukin-12-transduced murine lung cancer cells to GM-CSF or B7-1 (CD80) transfectants for therapeutic antitumor immunity in syngeneic immunocompetent mice.
Sumimoto H; Tani K; Nakazaki Y; Tanabe T; Hibino H; Wu MS; Izawa K; Hamada H; Asano S
Cancer Gene Ther; 1998; 5(1):29-37. PubMed ID: 9476964
[TBL] [Abstract][Full Text] [Related]
14. Granulocyte-macrophage colony-stimulating factor gene-transduced tumor cells combined with tumor-derived gp96 inhibit tumor growth in mice.
Kojima T; Yamazaki K; Tamura Y; Ogura S; Tani K; Konishi J; Shinagawa N; Kinoshita I; Hizawa N; Yamaguchi E; Dosaka-Akita H; Nishimura M
Hum Gene Ther; 2003 May; 14(8):715-28. PubMed ID: 12804136
[TBL] [Abstract][Full Text] [Related]
15. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
Gold JE; Zachary DT; Osband ME
Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
[TBL] [Abstract][Full Text] [Related]
16. OX40 ligand-transduced tumor cell vaccine synergizes with GM-CSF and requires CD40-Apc signaling to boost the host T cell antitumor response.
Gri G; Gallo E; Di Carlo E; Musiani P; Colombo MP
J Immunol; 2003 Jan; 170(1):99-106. PubMed ID: 12496388
[TBL] [Abstract][Full Text] [Related]
17. Concurrent administration of granulocyte colony-stimulating factor or granulocyte-monocyte colony-stimulating factor enhances the biological activity of rituximab in a severe combined immunodeficiency mouse lymphoma model.
Hernandez-Ilizaliturri FJ; Jupudy V; Reising S; Repasky EA; Czuczman MS
Leuk Lymphoma; 2005 Dec; 46(12):1775-84. PubMed ID: 16263581
[TBL] [Abstract][Full Text] [Related]
18. Vaccination with allogeneic GM-CSF gene-modified lung cancer cells: antitumor activity comparing with that induced by autologous vaccine.
Li H; Jiang HJ; Ma MQ; Wei F; An XM; Ren XB
Cancer Biother Radiopharm; 2007 Dec; 22(6):790-8. PubMed ID: 18158770
[TBL] [Abstract][Full Text] [Related]
19. Irradiated tumor cells adenovirally engineered to secrete granulocyte/macrophage-colony-stimulating factor establish antitumor immunity and eliminate pre-existing tumors in syngeneic mice.
Nagai E; Ogawa T; Kielian T; Ikubo A; Suzuki T
Cancer Immunol Immunother; 1998 Oct; 47(2):72-80. PubMed ID: 9769115
[TBL] [Abstract][Full Text] [Related]
20. Antitumor protection from the murine T-cell leukemia/lymphoma EL4 by the continuous subcutaneous coadministration of recombinant macrophage-colony stimulating factor and interleukin-2.
Vallera DA; Taylor PA; Aukerman SL; Blazar BR
Cancer Res; 1993 Sep; 53(18):4273-80. PubMed ID: 8364923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
